Overview

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborator:
Chipscreen Biosciences, Ltd.
Treatments:
chiglitazar
Vitamin E